Back to Trials
NCT01803451EARLY_PHASE1RecruitingAccepts Healthy Volunteers

Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

The University of Texas Health Science Center at San Antonio

Start Date

11/1/2005

Completion Date

8/1/2027

Summary

The overall goal of this project is to understand the mechanisms by which gastric bypass surgery improves glucose metabolism. The central hypothesis guiding this project is that the reconfiguration of intestinal transit with the Roux-en-Y will increase the release of insulinotropic GI hormones, termed incretins that improve insulin secretion and glucose metabolism. The study is divided into three specific aims. 1. To determine the role of incretin hormones on insulin secretion in patients with gastric bypass surgery using intravenous-oral hyperglycemic clamp. 2. To compare incretin effect and glucose tolerance among patient who suffer from hypoglycemia after RYGB and asymptomatic surgical and non-surgical individuals. 3. To quantify the contribution of GLP-1 to incretin effect enhancement following surgery.

Detailed Description

The overall goal of this project is to understand the mechanisms by which gastric bypass surgery improves glucose metabolism. The central hypothesis guiding this project is that the reconfiguration of intestinal transit with the Roux-en-Y will increase the release of insulinotropic GI hormones, termed incretins that improve insulin secretion and glucose metabolism. The study is divided into three specific aims. 1. To determine the role of incretin hormones on insulin secretion in patients with gastric bypass surgery using intravenous-oral hyperglycemic clamp. 2. To compare incretin effect and glucose tolerance among patient who suffer from hypoglycemia after RYGB and asymptomatic surgical and non-surgical individuals. 3. To quantify the contribution of GLP-1 to incretin effect enhancement following surgery.

Eligibility Criteria

Age Range: 18 years to 65 years

Inclusion Criteria: * age 18-65 * healthy control without diabetes or active organ disease * Individuals with bariatric surgery * recurrent hypoglycemia post gastric bypass Exclusion Criteria: * pregnancy * significant anemia * diabetes currently unless pre-op for bariatric surgery procedure * GI obstruction

Interventions

DRUG

exendin-(9-39)

DRUG

exendin -(9-39)

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Post-bariatric Surgery

Locations

Texas Diabetes Institute - University Health System

San Antonio, Texas 78207

United States

South Texas Veterans Health Care System

San Antonio, Texas 78229

United States